Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review by Anna C. Pavlick, DO, MBA, of New York University Perlmutter Cancer Center, and colleagues, who noted that while research in this area in rapidly progressing, the answer to this important question is still unclear, as nearly 50% of melanoma patients have a BRAF mutation.

Learn more by clicking here.